#NEWS – We’re excited to expand access to our biosimilar through a private-label agreement. Learn more: bit.ly/3UUBNOf

#NEWS : We are proud to announce our new collaboration with Walgreens and @EmVenioResearch to improve diversity and access in clinical trials. Learn more: bit.ly/4biHBqm

#NEWS – We’re proud to share that the FDA has approved an additional formulation of our biosimilar for patients living with certain chronic inflammatory diseases.

Learn more: bit.ly/4aUQOoN

#NEWS : We are proud to announce the U.S. FDA approval for the treatment of generalized pustular psoriasis ( #GPP ) in adults and pediatric patients 12 years of age and older. Learn more: bit.ly/48Yx2XL

#NEWS : We are continuing our successful collaboration with 3T Biosciences to develop more novel cancer immunotherapies for people living with cancer.

Learn more: bit.ly/3vosSKV

#ImmunoOncology #JPM2024

#NEWS : The U.S. FDA has granted Breakthrough Device designation to our investigational prescription digital therapeutic (PDT) developed in collaboration with Click Therapeutics® to potentially help treat the negative symptoms of #schizophrenia .
Learn more: bit.ly/3Lqu8RY

#NEWS : We're joining forces with IBM to further drug discovery for unmet patient needs. Our teams will collaborate to develop an unprecedented antibody design platform to accelerate our R&D.
Learn more: bit.ly/3Ritzxv

#ArtificialIntelligence #ResearchAndDevelopment

#NEWS : We are proud to announce that the U.S. FDA has granted Orphan Drug Designation to our investigational compound for the potential treatment of idiopathic pulmonary fibrosis ( #IPF ). Learn more: bit.ly/47uv0OD

#NEWS – We’re proud to share results from the first large-scale U.S. validation of a novel AI-driven model to predict risk of chronic kidney disease ( #CKD ) progression at all disease stages with Carelon Research at American Society of Nephrology #KidneyWk

Learn more: bit.ly/3FQpR7L

#NEWS : DAREON-5, a Phase II trial evaluating our investigational DLL3 T-cell engager for neuroendocrine carcinomas, has initiated. The U.S. FDA has granted this investigational compound with Orphan Drug Designation as well as Fast Track Designations. bit.ly/3Scd734

#NEWS – We’re pleased to share that our interchangeable biosimilar is now commercially available at a low wholesale acquisition cost.

Learn more: bit.ly/3ruBVrS

#NEWS – Chronic kidney disease (CKD) is a growing health issue that impacts more than 35 million adults in the U.S. Great news for patients: The U.S. FDA has approved our medication with Eli Lilly and Company for adults with #CKD .

Learn more: bit.ly/48kMhLA

#NEWS : The U.S. FDA has accepted our supplemental New Drug Application for review of our potential treatment of fibrosing interstitial lung disease (ILD) in children and adolescents. We are pleased the FDA recognizes this unmet need: bit.ly/46MZY5e

#NEWS – Our Interchangeable biosimilar is now included on Express Scripts’ National Preferred Formulary.

Learn more: bitly.ws/L6VS

#NEWS : Latest clinical data shows prevention of generalized pustular psoriasis ( #GPP ) flares, meeting the primary endpoint of the Effisayil 2 trial: bit.ly/43mgSF3

#NEWS – We’re proud to announce that our Interchangeable biosimilar for multiple chronic inflammatory diseases is now commercially available in the U.S.

Learn more: bitly.ws/JTXF

#PRESS : Boehringer Ingelheim, FIT’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease: bit.ly/44gSjdm

#NEWS : Our interchangeable #biosimilar that will launch in July received preferred formulary status with Optum for commercially insured patients.

Learn more: bitly.ws/JkfT

#NEWS – Did you know there are ~5,700 new cases of #Type2Diabetes in young people in the U.S. each year? We’re proud to share that the U.S. FDA has approved our medication with @LillyDiabetes for children 10 years and older with type 2 diabetes. Learn more: bit.ly/3XgSROb